Voting Rights and Shares Capital of the Company

Rhea-AI Summary

Nanobiotix (NBTX) has released its latest voting rights and shares capital update as of January 31, 2025. The company reported 47,426,851 shares outstanding, with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights.

Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, dual-listed on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.

Positive

• Owns portfolio of over 25 patent families across three nanotechnology platforms
• Dual-listed on major exchanges (Euronext Paris and Nasdaq)

Negative

• None.

News Market Reaction

+3.18%

1 alert

+3.18% News Effect

On the day this news was published, NBTX gained 3.18%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

PARIS, Feb. 12, 2025 (GLOBE NEWSWIRE) --

Paris, France, February 12, 2025
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, theoretical1	Total voting rights, exercisable2
January 31, 2025	47,426,851	49,208,659	49,186,541

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com

¹ The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

² The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed. 

Attachment

• 2025-02-12 -- NBTX -- Voting Rights & Shares Capital -- FINAL

FAQ

How many shares does Nanobiotix (NBTX) have outstanding as of January 31, 2025?

As of January 31, 2025, Nanobiotix (NBTX) has 47,426,851 shares outstanding.

What is the difference between NBTX theoretical and exercisable voting rights?

As of January 31, 2025, NBTX has 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights. The difference accounts for shares held in treasury by the company, which have suspended voting rights.

How many patent families does Nanobiotix own and in what areas?

Nanobiotix owns more than 25 patent families across three nanotechnology platforms: oncology, bioavailability and biodistribution, and disorders of the central nervous system.

When did Nanobiotix (NBTX) get listed on Nasdaq Global Select Market?

Nanobiotix (NBTX) has been listed on the Nasdaq Global Select Market since December 2020.